Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Inflammatory Cells From Various Pathologies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02270411
Recruitment Status : Recruiting
First Posted : October 21, 2014
Last Update Posted : August 28, 2019
Sponsor:
Information provided by (Responsible Party):
Innovaderm Research Inc.

Brief Summary:

The objective of this experiment is to develop and validate in vitro methods to isolate inflammatory cells from skin biopsies for quantitative flow cytometry analysis. Real-time polymerase chain reaction (RT-PCR) will also be performed using skin biopsy samples to validate flow cytometry results. Such methods could eventually be used to better understand the pathophysiology and the mechanism of action of various medications in patients with atopic dermatitis, acne rosacea or vulgaris, HS, and systemic sclerosis.

In this study, up to 15 healthy volunteers, 50 patients with atopic dermatitis, 15 patients with acne rosacea, 15 patients with psoriasis (to be used as control), 15 patients with acne vulgaris, 10 patients with psoriasis to develop a method of analysis for systemic sclerosis, and 10 patients with HS will be recruited.

For the healthy volunteers, atopic dermatitis, psoriasis and HS groups, at least one (1) and a maximum of four (4) skin biopsies (4-5 mm) per subject will be performed. Biopsies will be performed on either the trunk or the limbs, excluding the hands and the feet.

At least one (1) and a maximum of three (3) skin biopsies (2-3 mm) per subject will be collected for the acne rosacea and acne vulgaris groups from one or more body location(s) affected by the pathology.

For patients with atopic dermatitis, an optional blood draw of up to 10 mL will be collected to measure serum IgE levels. For patients with atopic dermatitis, psoriasis, and HS, an optional blood collection of up to 50 mL will be collected to perform flow cytometry on circulating blood cells to study differences in flow cytometry results between cells extracted from biopsies and circulating cells.


Condition or disease
Atopic Dermatitis Acne Rosacea Acne Vulgaris

Detailed Description:

Innovaderm, in collaboration with "The Immunoregulation laboratories of CRCHUM" and "McGill University division of dermatology", recently developed a novel 6-hour method to study IL-17A (Interleukin) and IL-22 from fresh biopsies of psoriatic patients. This reproducible experimental approach combines enzymatic digestion and mechanical dissociation for skin cell isolation. This is followed by a multi-color flow cytometry analysis in the absence of in vitro expansion and re-stimulation. Using this method, we examined the cellular source of IL-17A and IL-22 on a small number (20x10³) of viable CD45+ (Cluster of Differentiation Antigen 45) cells that are freshly isolated from 4 mm punch skin biopsies (n=22 patients with psoriasis). The method was used for the study on "Persistence of IL-17A+ T lymphocytes and IL-17A expression in psoriatic plaques refractory to ustekinumab therapy" presented during the 72nd annual meeting of the American Academy of Dermatology in Denver. A detailed presentation of this method will be done during the upcoming annual meeting of the Society for Investigative Dermatology in Albuquerque, New Mexico.

We would like to investigate and adapt this method for other dermatological conditions such as Atopic Dermatitis, Acne Rosacea and Acne Vulgaris.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 130 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Development of a Method to Isolate Inflammatory Cells From Skin Biopsies of Patients With Various Pathologies for Quantitative Flow Cytometry Analysis
Study Start Date : May 2014
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne Biopsy Rosacea

Group/Cohort
Healthy Subjects
Healthy subjects.
Atopic Dermatitis
Patient has a history of atopic dermatitis for at least 6 months. Subject has clinically confirmed diagnosis of active atopic dermatitis, according to Hanifin and Rajka criteria.
Acne Rosacea
Patient has a history of acne rosacea for at least 6 months.
Acne Vulgaris
Patient has a history of acne vulgaris for at least 6 months.
Psoriasis
Patient has a history of psoriasis for at least 6 months.
Hidradenitis Suppurativa (HS)
Patient has a history of HS for at least 6 months.



Primary Outcome Measures :
  1. Proportion of Inflammatory Cells in Skin Biopsies [ Time Frame: 1 Day ]
    The proportion of inflammatory cells in skin biopsies will be assessed by flow cytometry.


Secondary Outcome Measures :
  1. Expression of Inflammation-Related Genes in Skin Biopsies [ Time Frame: 1 Day ]
    The level of expression of inflammation-related genes in skin biopsies will be assessed by quantitative real-time polymerase chain reaction (qRT-PCR).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Invitation to volunteer
Criteria

Inclusion Criteria:

  • Subject, male or female, is aged 18 years or older at the screening visit.
  • Female subjects of childbearing potential must have a negative urine pregnancy test at the Screening visit.
  • Subjects must be able and willing to provide written informed consent and comply with the requirements of this study protocol.

    **Special inclusion criterion for volunteers with atopic dermatitis, acne rosacea, acne vulgaris, psoriasis, or HS

  • Patient has a history of atopic dermatitis, acne rosacea, acne vulgaris, psoriasis, or HS for at least 6 months.

    **Special inclusion criterion for volunteers with atopic dermatitis

  • Subject has clinically confirmed diagnosis of active atopic dermatitis, according to Hanifin and Rajka criteria

Exclusion Criteria:

  • Female subject is pregnant or lactating
  • Subject is currently participating in a clinical trial with an experimental drug or device
  • Subject is known to have hepatitis B or hepatitis C viral infection
  • Subject is known to have immune deficiency or is immunocompromised
  • Subject has a known hypersensitivity/allergy to lidocaine
  • Patient has a history of keloids
  • Patient is taking heparin, warfarin or has a contraindication to skin biopsies.
  • Patient has used systemic medication, medical devices or natural health products to treat acne rosacea, atopic dermatitis, acne vulgaris, psoriasis, or HS, or UVB phototherapy within 4 weeks of biopsy day
  • Patient has used oral, intravenous, intramuscular or intra-lesional or intra-articular steroids, or immunosuppressive medication within 4 weeks of biopsy day
  • Patient has used a biologic agent within 24 weeks or 5 half-lives (whichever is longer) of biopsy day
  • Patient has used topical medication, natural health products or medical devices to treat acne rosacea, atopic dermatitis, acne vulgaris, psoriasis, or HS on the areas to be biopsied within 2 weeks of biopsy day
  • Patients is currently using or has used isotretinoin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02270411


Contacts
Layout table for location contacts
Contact: Stéphanie Légaré 514-521-4285 ext 284 slegare@innovaderm.ca

Locations
Layout table for location information
Canada, Quebec
Innovaderm Research Recruiting
Montreal, Quebec, Canada, H2K 4L5
Contact: MARIE-JOSEE MENARD    514-521-4285 ext 380    mjmenard@innovaderm.ca   
Principal Investigator: Robert Bissonnette, MD         
Sub-Investigator: Catherine Maari, MD         
Sponsors and Collaborators
Innovaderm Research Inc.
Investigators
Layout table for investigator information
Principal Investigator: Robert Bissonnette, MD Innovaderm Research

Layout table for additonal information
Responsible Party: Innovaderm Research Inc.
ClinicalTrials.gov Identifier: NCT02270411     History of Changes
Other Study ID Numbers: Inno-6036
First Posted: October 21, 2014    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Acne Vulgaris
Rosacea
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Acneiform Eruptions
Sebaceous Gland Diseases